Article Per Year (5 Year)
p-Index From 2019 - 2024
0.408
P-Index
This Author published in this journals
All Journal JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Arina Dery Puspitasari
Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia
Chemistry Education Health Professions Medicine & Pharmacology Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
A Community's Knowledge and Attitude in Recognizing Symptoms and Diarrhea Management in Children Arina Dery Puspitasari; Novitri Wulandari; Bindaria Mutmaina Prabawati; Liza Yudistira Yusan
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 2 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v9i22022.101-106

Abstract

Background: Diarrhea is the world's second-biggest cause of death among children. Children suffer from severe dehydration due to the lack of understanding of treating diarrhea properly. Objective: This study aimed to assess the level of community knowledge and attitudes toward the treatment of diarrhea in children. Methods: This was an observational, cross-sectional study conducted in a community in Gresik, Indonesia, in 2019. A Likert scale questionnaire, consisting of 10 items on knowledge and five on community attitudes on diarrhea management in children, was used to collect data. Results: One hundred and seven participants responded to the survey, and 89.72% were women. 'Respondents' mean age was 41.84 ± 11.27 years with various levels of education. It was found that the community had good knowledge of diarrhea management in children, as shown by the finding that 84.11% of the participants provided the correct answers. About 87.85% of the participants were aware of the signs and symptoms of diarrhea in children. However, there is still a shortage of understanding about managing diarrhea properly, particularly when identifying the necessary medicine. About 89.72% of the participants demonstrated a "positive" attitude in diarrhea management, while approximately 78.51% agreed that children with diarrhea should be given oral rehydration. Conclusion: The knowledge about recognizing signs and symptoms of diarrhea in children was good, while the knowledge about diarrhea management needed to be improved. Overall, the respondents had a positive attitude about diarrhea management in children.
Isoprinosine along with Favipiravir or Oseltamivir in Patients with Moderate Covid-19 at RSD Dr. Soebandi Jember Chrysnanda Maryska; Didik Hasmono; Sofiati Diah Baisuni; Ayunda Nur Hidayatiningsih; Arina Dery Puspitasari; Retna Dwi Puspitarini; Budi Suprapti
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 3 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v9i32022.209-219

Abstract

Background: Isoprinosine is an immunomodulator that is now being used to treat Covid-19 patients. Objectives: To evaluate Isoprinosine with Favipiravir or Oseltamivir in moderate Covid-19. Methods: In a retrospective observational analysis, in-hospital moderate Covid-19 patients treated between June 2020 and June 2021 were included. Results: Inclusion criteria for 364 patients were met, with 135 receiving Favipiravir-Isoprinosine (Group 1) and 229 receiving Oseltamivir-Isoprinosine (Group 2). In group 1, the majority of patients (58.50%) were female (35.60%), had no comorbidities (71.60%), were discharged with a positive PCR (74.80%), did not require a breathing apparatus (99.26%), had leukocyte levels between 4,5-11,0 (82.22%), lymphocyte levels between 25-33 (34.07%), and were discharged with no ground-glass opacity (34.07%) (54.10%), LOS was 9-13 days (50.37%), while the mortality rate was 0.70%. In group 2, the majority of patients were male (54.10%), with the highest age range being 42-56 years (35.80%), without comorbidities (69.0%), discharged with a positive PCR (72.50 %), and without the need for a breathing apparatus (99.13%), with leukocyte levels ranging from 4.5 – 11.0 (81.22 %), with lymphocyte levels ranging from 25.0 – 33.0 (26.20 %), and were discharged with no ground-glass opacity (49.34 %), LOS was 9 - 13 days (34.06 %), and the mortality rate was 0.87%.Conclusion: In this trial, it was determined that combining isoprinosine with antivirals favipiravir or Oseltamivir could produce significant clinical improvement.
Co-Authors Ayunda Nur Hidayatiningsih Bindaria Mutmaina Prabawati Budi Suprapti Chrysnanda Maryska Didik Hasmono Liza Yudistira Yusan Novitri Wulandari Retna Dwi Puspitarini Sofiati Diah Baisuni